Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.38 18.97% 4.9M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.42 -1.62% 82K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Published: 2021-01-26 (Crawled : 13:03) - globenewswire.com
VIR | $8.18 -0.85% 270K
|
Health Technology
|
| O: 1.37%
H: 73.96%
C: 71.96%
hepatitis trial phase 3 phase 1 phase 2 injection ongoing infections chronic hepatitis b
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
Published: 2020-12-14 (Crawled : 13:05) - globenewswire.com
BCDA | $0.363 -1.39% 53K
|
Health Technology
|
| O: 10.28%
H: 123.47%
C: 44.05%
heart phase 3 trial cardiamp
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Published: 2021-08-10 (Crawled : 13:00) - biospace.com/
FULC | $7.15 140K
|
Health Technology
|
| O: 58.58%
H: 67.22%
C: 42.09%
disease phase 1 positive results trial phase 2 phase 3
Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Published: 2020-09-08 (Crawled : 12:07) - globenewswire.com
SPRO | $1.52 1.33% 70K
|
Health Technology
|
| O: 3.35%
H: 54.43%
C: 41.14%
positive results phase 3 trial topline injection infections
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Published: 2021-09-27 (Crawled : 23:00) - globenewswire.com
ALT | $7.04 1.7M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
phase 1 trial phase 2 phase 3
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
ALT | $7.04 1.7M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
positive results phase 1 positive results trial obesity phase 2 phase 3
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
Published: 2021-05-19 (Crawled : 22:00) - globenewswire.com
SNSE | $1.02 2.0% 24K
|
|
| O: 0.82%
H: 35.47%
C: 29.05%
ongoing phase 1 iot trial phase 3 phase 2 cell carcinoma
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
TGTX | $14.47 4.7% 1.6M
|
Health Technology
|
| O: 11.75%
H: 29.43%
C: 26.04%
positive therapy multiple sclerosis results sclerosis phase 3 treatment topline
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
Published: 2021-03-11 (Crawled : 16:02) - biospace.com/
XCUR 4 | $0.5838 -2.29% 20K
|
Commercial Services
|
| O: 2.58%
H: 28.64%
C: 25.63%
results trial nu-0129 phase 3 phase 1 phase 2 glioblastoma
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Published: 2021-01-11 (Crawled : 23:00) - globenewswire.com
MRUS | $40.5 -1.34% 99K
|
Health Technology
|
| O: -3.57%
H: 27.15%
C: 24.76%
test cancer gastrointestinal phase 3 phase 1 phase 2 symposium
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
Published: 2020-08-24 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -72.75%
H: 44.62%
C: 24.6%
results phase 3 trial topline
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -0.26%
H: 26.97%
C: 24.14%
phase 3 phase 1 phase 2 enroll glioblastoma
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Published: 2021-06-24 (Crawled : 12:15) - globenewswire.com
CRBP M | $36.365 -2.14% 51K
|
Health Technology
|
| O: -15.58%
H: 24.4%
C: 23.21%
treatment results topline phase 3
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2021-10-28 (Crawled : 14:00) - biospace.com/
RFL 4 | $1.735 -2.53% 5.2K
|
Finance
|
| O: -78.09%
H: 36.16%
C: 22.39%
myeloid leukemia cancer leukemia phase 3 trial pancreatic cpi-613 pancreas acute myeloid leukemia
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | $13.185 0.27% 570K
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $144.54 -0.16% 4.9M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $27.07 -2.06% 260K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Published: 2022-06-13 (Crawled : 12:20) - biospace.com/
OPTN | $0.961 -5.78% 260K
|
Health Services
|
| O: 17.49%
H: 31.63%
C: 21.4%
treatment trial positive topline phase 3
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedixCompany Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
BIVI | $0.4836 2.59% 1.1M
|
Health Technology
|
| O: 0.87%
H: 21.8%
C: 20.6%
alzheimer biopharma acquisition mid-2021 phase 3 trial enroll alzheimer’s alzheimer's
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.